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Ribociclib is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European 33 
Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC). The pivotal trial showed a 34 
significant improvement in progression-free survival when compared to endocrine therapy alone. However, having a 35 
challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a concern when combined to 36 
radiotherapy (RT) with palliative approach. 37 
There are no available published data regarding the combination of ribociclib and palliative RT. We reported our 38 
preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University 39 

























Viewpoints and Debates 63 
Ribociclib (Kisqali
®
; Novartis, Basel, Switzerland) is a CDK4-6 inhibitor recently approved by the Food and Drug 64 
Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer 65 
(MBC). The pivotal trial showed a significant improvement in progression-free survival when compared to endocrine 66 
therapy alone [1]. 67 
However, having a challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a 68 
concern when combined to radiotherapy (RT) with palliative approach. Nevertheless, inhibition of CDK4/6 has shown 69 
to exert a protective effect on radiation-induced gastrointestinal toxicity in a preclinical model [2]. Therefore, the 70 
association of this class of drugs with RT could represent a beneficial combination. 71 
There are no available published data regarding the combination of ribociclib and palliative RT in a clinical setting. A 72 
recently published preliminary report on five patients treated with palbociclib and radiation at the Institut Curie (Paris, 73 
France) showed encouraging results [3]. 74 
We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence 75 
University (Florence, Italy) giving palliative RT concomitant to ribociclib (600 mg once daily; 3 × 200-mg tablets; 21 76 
consecutive days of treatment, followed by 7 days off treatment) plus letrozole (2.5 mg tablet; once daily throughout the 77 
28-day cycle) as first-line treatment for MBC. 78 
Main patients’ series characteristics are summarized in Table 1. In all cases, RT was prescribed with palliative/analgesic 79 
intent due to symptomatic bone metastases. Two patients had bone-only disease, three patients both bone and visceral 80 
disease (two lung, one liver). 81 
Hematological and non-hematological toxicities were assessed during the second 21-days cycle of ribociclib, following 82 
the concomitant delivery of RT and the first cycle of ribociclib. Major recorded adverse events confirmed a safety 83 
profile of the combined approach in line with main published data [1,4,5]. No RT course was suspended, and all 84 
patients had pain relief. 85 
Ribociclib treatment suspension was required in two cases, for two weeks. Treatment recovery (first dose reduction; 86 
400 mg; 2 x 200-mg tablets) was observed in both cases, while letrozole was never suspended. 87 
At time of the present analysis, all the patients are still on first-line treatment: three patients received four cycles and 88 
two patients five cycles of ribociclib. At 3-month assessment (clinical visit, thorax/abdomen computed tomography 89 
scan, bone scan), three stable disease and two partial response were observed. 90 
Even though the toxicity profile of concomitant ribociclib and RT requires further large investigations, our very 91 
preliminary data showed encouraging results and a safety in line with data deriving from pivotal trials. Prospective 92 
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Table 1. Main patients and treatments characteristics. 






















1 71 0 Left femoral neck 30/5 VMAT 1 Neutropenia No No Yes Yes 2 
2 55 0 
Bilateral femoral 
neck 
20/5 3DCRT 1 No No No Yes No 0 
3 76 2 Right hip 20/5 3DCRT 1 No 
Diarrhea 
Vomiting 
No Yes Yes 2 
4 79 1 
Lumbar spine 
(L2-L3) 
20/5 3DCRT 1 No No No Yes No 0 
5 36 0 
Cervical/thoracic 
spine (C3-T2) 
20/5 3DCRT 1 No No No Yes No 0 
Abbreviations: PS, performance status; Dose/fx, total dose (Gy)/number of fractions; G3-4, grade 3-4; RT, radiotherapy; VMAT, volumetric modulated arc therapy; 3DCRT, 3-
dimensional conformal radiotherapy. 
*Toxicity recorded after the cycle of combined treatment ribociclib/letrozole with palliative radiation. 




Click here to download Additional Files (Article Transfer): Highlights_rev.docx
